Novo Nordisk Stock: Buy or Sell? | NVO Stock Analysis
Summary
Parkev analyzes the current state of Novo Nordisk, noting that the stock is down 8% year-to-date in 2026 despite the proliferation of GLP-1 weight loss treatments. While historical revenue has tripled since 2017, Parkev points out that growth is expected to stall, with a projected 6.3% revenue decline in 2026. Parkev emphasizes that the company's operating profit margins remain excellent at 45.4%, and the true value of the investment lies in Novo Nordisk's long-term research and development capabilities to innovate new drugs beyond the current weight loss trend.
Parkev expresses concern regarding the downward trend in Return on Invested Capital (ROIC), which has fallen from over 80% a decade ago to 37%. However, Parkev notes that the ROIC still significantly exceeds the weighted average cost of capital. By updating a discounted cash flow model, Parkev arrived at a fair value estimate that suggests the stock is currently trading at a significant discount to its intrinsic value.
Mentioned Stocks
Reasoning: Parkev reiterates the buy rating because the stock appears deeply undervalued. Parkev calculates a fair value of $123 per share using a discounted cash flow model, which is well above the current market price of $47. Additionally, Parkev notes the forward P/E ratio of 14.14 is near historical lows, and the company maintains strong operating margins above 45% despite temporary revenue headwinds projected for 2026.